In vivo experimentation was conducted with KPCA.B cells to identify a potential benefit in combining 5-aza, givinostat (HDACi), and ICB (PD-L1/CTLA-4) in syngeneic HGSOC tumor models that recapitulate the clinical disease and ICB responses [41]. The gene discussed is CTLA4; the disease is neoplasm.